Health Care & Life Sciences » Biotechnology | Microbix Biosystems Inc.

Microbix Biosystems Inc. | Balance Sheet

Fiscal year is October-September. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
260.00
547.40
104.20
5.40
54.50
44.40
Total Accounts Receivable
1,229.70
2,285.10
1,842.30
2,204.30
1,487.30
1,405.70
Inventories
1,072.20
1,598.40
3,625.30
3,396.00
4,467.10
4,447
Other Current Assets
75.80
276.10
216.40
55.50
153.00
170
Total Current Assets
2,637.80
4,707.00
5,788.20
5,661.20
6,161.80
6,067
Net Property, Plant & Equipment
5,929.20
8,751.80
11,867.50
12,252.00
12,211.80
6,646.70
Total Investments and Advances
250.00
-
-
-
-
-
Intangible Assets
3,883.50
4,053.40
5,361.30
6,204.30
6,484.00
5,016.30
Other Assets
15.60
221.70
-
-
-
-
Total Assets
12,716.00
17,998.90
23,547.00
25,247.50
26,437.60
19,310.10
ST Debt & Current Portion LT Debt
119.80
814.10
1,457.90
2,667.00
2,529.10
Accounts Payable
1,353.60
1,825.60
2,369.60
1,898.50
2,842.00
Other Current Liabilities
0.00
0.00
308.00
683.50
1,145.20
Total Current Liabilities
1,473.50
2,639.70
4,135.50
5,249.00
6,516.20
Long-Term Debt
7,807.90
7,456.00
8,086.00
7,058.20
7,650.50
Deferred Taxes
-
265.00
530.00
1,130.00
1,580.00
Other Liabilities
412.70
412.70
-
-
-
Total Liabilities
9,694.00
10,508.30
12,221.50
12,307.10
14,166.70
Common Equity (Total)
3,022.00
7,490.60
11,325.50
12,940.30
12,270.90
Total Shareholders' Equity
3,022.00
7,490.60
11,325.50
12,940.30
12,270.90
Total Equity
3,022.00
7,490.60
11,325.50
12,940.30
12,270.90
Liabilities & Shareholders' Equity
12,716.00
17,998.90
23,547.00
25,247.50
26,437.60

About Microbix Biosystems

View Profile
Address
265 Watline Avenue
Mississauga Ontario L4Z 1P3
Canada
Employees -
Website http://www.microbix.com
Updated 07/08/2019
Microbix Biosystems, Inc. engages in the manufacture of viral and bacterial antigens and reagents for the global diagnostics industry. Its biological solutions include products for human health applications in the vaccine, therapeutic and diagnostic markets, and a product for the worldwide animal reproduction market. Its pipeline of technologies and products include LumiSort, semen sexing technology for the livestock industries; and Kinlytic, a thrombolytic drug for life-threatening blood clots.